Fate therapeutics posts q3 loss per share of $0.40

Fate therapeutics reports third quarter 2019 financial results and highlights operational progress.q3 revenue $2.4 million versus $1.0 million.q3 revenue estimate $1.8 million -- refinitiv ibes data.qtrly net loss per common share $0.40.q3 earnings per share view $-0.38 -- refinitiv ibes data.

FATE Ratings Summary

FATE Quant Ranking